炎症性タンパク質の働きを止めるとマウスの健康寿命が延びる(Turning off inflammatory protein extends healthy lifespan in mice)

ad

2024-07-19 インペリアル・カレッジ・ロンドン(ICL)

英国とシンガポールの研究者は、重要な炎症タンパク質IL-11の生成を抑えることで、マウスの寿命を延ばし、老化関連疾患を減少させ、老化による虚弱性を軽減できることを発見しました。IL-11遺伝子を削除したマウスは平均で20%以上寿命が延びました。また、75週齢(人間の約55歳相当)のマウスに抗IL-11抗体を注射した結果、オスで22.4%、メスで25%寿命が延びました。この治療により、がんや線維症、慢性炎症による死亡が減少し、副作用もほとんどありませんでした。研究はマウスで行われたものの、人間にも同様の効果が期待されます。抗IL-11治療は現在、他の病状のために臨床試験中であり、将来的には人間の老化に対する効果も研究される可能性があります。

<関連情報>

IL-11シグナルを阻害すると哺乳類の健康寿命が延びる Inhibition of IL-11 signalling extends mammalian healthspan and lifespan

Anissa A. Widjaja,Wei-Wen Lim,Sivakumar Viswanathan,Sonia Chothani,Ben Corden,Cibi Mary Dasan,Joyce Wei Ting Goh,Radiance Lim,Brijesh K. Singh,Jessie Tan,Chee Jian Pua,Sze Yun Lim,Eleonora Adami,Sebastian Schafer,Benjamin L. George,Mark Sweeney,Chen Xie,Madhulika Tripathi,Natalie A. Sims,Norbert Hübner,Enrico Petretto,Dominic J. Withers,Lena Ho,Jesus Gil,… Stuart A. Cook
Nature  Published:17 July 2024
DOI:https://doi.org/10.1038/s41586-024-07701-9

炎症性タンパク質の働きを止めるとマウスの健康寿命が延びる(Turning off inflammatory protein extends healthy lifespan in mice)

Abstract

For healthspan and lifespan, ERK, AMPK and mTORC1 represent critical pathways and inflammation is a centrally important hallmark1,2,3,4,5,6,7. Here we examined whether IL-11, a pro-inflammatory cytokine of the IL-6 family, has a negative effect on age-associated disease and lifespan. As mice age, IL-11 is upregulated across cell types and tissues to regulate an ERK–AMPK–mTORC1 axis to modulate cellular, tissue- and organismal-level ageing pathologies. Deletion of Il11 or Il11ra1 protects against metabolic decline, multi-morbidity and frailty in old age. Administration of anti-IL-11 to 75-week-old mice for 25 weeks improves metabolism and muscle function, and reduces ageing biomarkers and frailty across sexes. In lifespan studies, genetic deletion of Il11 extended the lives of mice of both sexes, by 24.9% on average. Treatment with anti-IL-11 from 75 weeks of age until death extends the median lifespan of male mice by 22.5% and of female mice by 25%. Together, these results demonstrate a role for the pro-inflammatory factor IL-11 in mammalian healthspan and lifespan. We suggest that anti-IL-11 therapy, which is currently in early-stage clinical trials for fibrotic lung disease, may provide a translational opportunity to determine the effects of IL-11 inhibition on ageing pathologies in older people.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました